PE Sharpens Focus on MedTech Carve-Outs, Take-Privates

Private equity investment in the medical technology (MedTech) sector is becoming more concentrated, with deal value up 160% in the first half of 2026 over the prior year while deal volume rose only 5%. Investors are pursuing fewer, larger deals, focusing on two main strategies: carve-outs of non-core divisions from large strategic MedTech companies and take-private acquisitions of publicly traded firms whose long-term value may be underestimated by the market.

This trend creates significant opportunities for both PE clients and the large MedTech companies they transact with. For deal counsel, the shift requires a deeper, more nuanced approach to diligence. Success depends on understanding complex separation issues in carve-outs and navigating heightened FDA regulatory scrutiny. The FDA's new risk-based inspection program and focus on clinical trial reporting compliance can create significant valuation and liability risks if not addressed early in the M&A process.

Counsel should advise PE clients to integrate FDA and CMS reimbursement expertise into diligence from the outset. Key areas to watch include a target's history of adverse-event reporting, compliance with the new Quality Management System Regulation, and the operational complexities of separating a business from its parent. As more high-quality assets become available, competition will increase, rewarding investors who can accurately price these regulatory and execution risks.